AI Polypharmacology-Based Repurposing Research

Multi-Target Drug Interaction Prediction via Graph Neural Networks

This research investigates how graph neural networks can model complex protein-drug interaction networks to predict off-target effects and therapeutic synergies across multiple biological pathways. The work produces machine learning frameworks that identify novel drug combinations and single agents with unexpected polypharmacological benefits for disease treatment.

Deep Learning Models for Adverse Polypharmacology Effect Mitigation

This research studies deep neural networks trained on multi-omics datasets to predict and classify adverse drug interactions arising from unintended polypharmacological effects. The research generates computational models that enable safer drug repurposing strategies by quantifying toxicity risks before clinical translation.

Transformer-Based Pharmacophore Discovery for Disease-Agnostic Targets

This research explores transformer architectures to identify shared molecular pharmacophores across structurally diverse drugs targeting phenotypically similar diseases. The work produces interpretable AI models that reveal hidden therapeutic mechanisms enabling rapid cross-indication drug repositioning.

Protein Conformational Dynamics and Allosteric AI Drug Binding Analysis

This research investigates machine learning approaches to model dynamic protein conformations and predict allosteric binding sites for non-competitive drug interactions. The research generates novel insights into polypharmacological drug mechanisms by identifying previously unknown binding pockets for repurposing candidates.

Genomic Biomarker Integration for Polypharmacology Patient Stratification

This research studies AI-driven integration of genomic variation, expression profiles, and drug response data to identify patient subpopulations benefiting from polypharmacological drug effects. The work produces precision medicine frameworks that optimize repurposed drug efficacy through personalized biomarker-driven selection.

Natural Language Processing of Literature for Cryptic Drug Repurposing Signals

This research applies advanced NLP and text mining to biomedical literature to extract implicit pharmacological relationships and unreported drug-disease associations hidden in scientific publications. The research generates discovery pipelines that surface candidate drugs for repurposing before formal clinical investigation.

Metabolic Pathway Simulation for Polypharmacological Off-Target Activity Prediction

This research develops AI-driven metabolic modeling systems to simulate drug biotransformation and predict pharmacologically active metabolites with unintended therapeutic or toxic effects. The work produces computational systems that reveal additional treatment mechanisms from existing drugs through metabolite-target interaction analysis.

Federated Learning for Distributed Polypharmacology Network Pharmacology Studies

This research investigates federated machine learning architectures enabling collaborative AI training across institutional drug screening databases without centralizing proprietary data. The research generates robust polypharmacology prediction models by leveraging decentralized multi-institutional datasets for improved generalization.

Causal Inference Models for Drug-Target-Phenotype Relationship Elucidation

This research applies causal machine learning to disentangle direct drug effects from downstream cascade effects across biological networks to identify true mechanistic drivers of repurposing opportunities. The work produces causal models that distinguish genuine therapeutic polypharmacology from spurious correlations in drug response data.

Zero-Shot Learning for Orphan Disease Polypharmacology Drug Recommendations

This research develops zero-shot and few-shot learning models trained on well-characterized diseases to extrapolate polypharmacological drug predictions to understudied rare genetic disorders. The research generates novel therapeutic hypotheses for orphan diseases by transferring learned polypharmacology patterns from data-rich disease models.